Oncology JP Morgan 2023 – Adi Hoess pharmaphorum editor-in-chief Jonah Comstock joins Adi Hoess, CEO of Affimed, at the Zeppelin Hotel in San Francisco, to learn about
News AACR: Affimed builds case for natural killer cell therapy Affimed says new data from a phase 1/2 trial of its natural killer (NK) cell engager therapy AFM13 provide further evidence of its efficacy in treating CD30+ Hodgkin and non-Hodgkin lymphom
News Affimed and Roche ink $5bn plus cancer immunotherapy deal Deal is based on natural killer cell therapeutics
News Flagship joins three biotechs together to form Etcelera Flagship Pioneering has formed a new AI-focused biotech company, called Etcelera, by combining the platforms of three firms from its portfolio.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
